GlassScriptPhysician profile
Mohammad Pourmandi
NPI 1437730652
$3,017.02
in general payments reported to CMS, 2019-2025
15 companies · $16.11 in 2025
The $16.11 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $219 · 2022: $1,090 · 2023: $861 · 2024: $831 · 2025: $16.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,707.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $583.09 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $500.69 | 2022-2024 | Airsupra, Fasenra |
| Genzyme Corporation | $368.70 | 2022-2024 | |
| Glaxosmithkline, LLC. | $236.19 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.86 | 2024 | Jardiance |
| Arcutis Biotherapeutics, INC. | $220.64 | 2023-2024 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $219.32 | 2021-2022 | |
| Novo Nordisk INC | $149.92 | 2022-2023 | Wegovy |
| Penumbra, INC. | $125.00 | 2023 | Indigo System |
| Regeneron Healthcare Solutions, INC. | $118.76 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $114.00 | 2024 | Uptravi, Opsumit |
| Pfizer INC. | $83.15 | 2023 | |
| Merck Sharp & Dohme LLC | $23.15 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.44 | 2023 | Xifaxan |
| Coopersurgical, INC. | $16.11 | 2025 | Paragard T 380a |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Pourmandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.